Welcome to our dedicated page for Natera SEC filings (Ticker: NTRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Natera, Inc. (NASDAQ: NTRA) is a medical laboratories company focused on cell-free DNA testing and precision medicine in oncology, women’s health, and organ health. As a publicly traded issuer on the Nasdaq Stock Market LLC (Nasdaq Global Select Market), Natera files periodic and current reports with the U.S. Securities and Exchange Commission (SEC), which provide insight into its operations, financial condition, and material events.
On this SEC filings page, Stock Titan aggregates Natera’s regulatory documents, such as current reports on Form 8-K. For example, a recent Form 8-K filing describes the company’s release of quarterly financial results and an accompanying investor presentation, and confirms that Natera’s common stock, par value $0.0001 per share, is registered under the symbol NTRA on Nasdaq. These filings help investors understand how test volumes, revenue trends, and other operational metrics relate to Natera’s diagnostic and research activities.
Stock Titan enhances these filings with AI-powered summaries that explain key sections in accessible language, helping users interpret complex disclosures without replacing the original documents. Real-time updates from the SEC’s EDGAR system ensure that new Natera filings are added promptly, whether they involve earnings announcements, significant collaborations, or other reportable events.
Users interested in Natera’s precision medicine business can use this page to review historical and recent filings, track how the company discusses its oncology, women’s health, and organ health portfolios over time, and monitor material developments affecting NTRA. For deeper analysis, AI-generated highlights point to important items within lengthy filings so readers can focus on sections most relevant to their research or investment questions.
Natera (NTRA) reported an insider transaction on a Form 4. On 11/03/2025, the Executive Chairman, who is also a Director, sold 17,100 shares of common stock at a $200.0002 weighted average price, executed under a Rule 10b5-1 trading plan adopted on June 13, 2025. Following the sale, the reporting person beneficially owns 2,303,752 shares directly and 5,000 shares indirectly through a spouse. The sale price reflects multiple trades between $200.00 and $200.01 per share.
Natera (NTRA) CEO and President, who also serves as a Director, reported two sales of common stock. On 10/27/2025, he sold 2,335 shares at $192.324, and on 10/28/2025, he sold 3,680 shares at $191.4619. Following these transactions, he beneficially owned 149,840 shares.
The filing states both sales were executed to satisfy tax withholding obligations tied to RSU vesting and were made pursuant to a written instruction intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Natera, Inc. (NTRA): CFO reported open‑market sales on Form 4. The Chief Financial Officer executed multiple sales of common stock on 10/27/2025, 10/28/2025, and 10/29/2025. Reported transactions include 781 shares at $192.324 on 10/27, 1,237 shares on 10/28 at a weighted average price, and additional sales on 10/28 and 10/29 at weighted average prices within stated ranges. Following the reported transactions, the officer directly owned 64,126 shares.
Footnotes state that the 10/27 sale and the first 10/28 sale were effected to satisfy tax withholding and remittance obligations upon RSU vesting, pursuant to a written instruction intended to satisfy Rule 10b5‑1(c). The remaining sales were effected under a Rule 10b5‑1 trading plan adopted on June 14, 2024. Several prices are reported as weighted averages with detailed per‑trade ranges available upon request.
Natera, Inc. (NTRA) reported insider activity as a director and co‑founder filed a Form 4 disclosing small open‑market sales tied to RSU tax withholding. On 10/27/2025, the reporting person sold 288 shares at $192.324. On 10/28/2025, they sold 191 shares at $191.4619. Following these transactions, the filer reported 235,921 shares held directly. The filing also lists indirect holdings of 28,032 shares each by Caraluna 1 Trust and Caraluna 2 Trust. The sales were executed under a Rule 10b5‑1(c) written instruction connected to RSU vesting.
Natera (NTRA) reported an insider transaction by its SEC and Chief Legal Officer. The officer sold 935 shares of common stock on 10/27/2025 at $192.324 and 1,058 shares on 10/28/2025 at $191.4619. Both sales were made to satisfy tax withholding obligations related to RSU vesting and were executed under a written instruction intended to satisfy Rule 10b5-1(c).
Following these transactions, the officer beneficially owned 201,699 shares directly.
Natera (NTRA) reported insider transactions by its President, Clinical Diagnostics. The reporting person sold 1,008 shares of common stock at $192.324 on 10/27/2025 and 1,198 shares at $191.4619 on 10/28/2025. These sales were made to satisfy tax withholding and remittance obligations related to RSU vesting and were executed pursuant to a written instruction intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Following the transactions, beneficial ownership was 116,259 shares after the first sale and 115,061 shares after the second sale, held directly.
Natera, Inc. (NTRA): Form 4 insider transaction
The company’s President and Chief Business Officer reported open-market sales tied to RSU tax withholding under a Rule 10b5-1(c) plan. On 10/27/2025, 781 shares of common stock were sold at $192.324. On 10/28/2025, 928 shares were sold at $191.4619. Following these transactions, the reporting person directly owned 150,699 shares.
Natera (NTRA) reported insider activity by its Chief Financial Officer. On 10/22/2025, the CFO sold 920 shares at $186.68 and converted 1,250 Restricted Stock Units (RSUs) into common stock. Additional sales included 495 shares at $187.16 on 10/23/2025 (to satisfy tax withholding on RSU vesting) and 755 shares at $196.77 on 10/24/2025. Following these transactions, the officer directly owned 69,189 shares. The sales on 10/22 and 10/24 were made under a Rule 10b5-1 plan adopted on June 14, 2024.
Natera, Inc. (NTRA) insider transaction: A reporting person who serves as Executive Chairman and Director sold 10,000 shares of Natera common stock on 10/20/2025 at a price of $190 per share, coded as an open-market sale (S). The trade was executed under a Rule 10b5-1 trading plan adopted on June 13, 2025.
Following the transaction, the reporting person beneficially owned 2,320,852 shares directly and 5,000 shares indirectly through a spouse.
Natera, Inc. (NTRA) — Form 4 insider activity: Co‑founder and director reported RSU vesting and a related tax sale. On 10/20/2025, 190 Restricted Stock Units were converted to common stock (code M). On 10/21/2025, 93 shares were sold at $187.95 (code S) to satisfy tax withholding, pursuant to a Rule 10b5‑1(c) instruction. Following these transactions, the reporting person beneficially owned 236,302 shares directly. In addition, 28,032 shares are held indirectly by Caraluna 1 Trust and 28,032 shares by Caraluna 2 Trust.